MOATAZEDI DAVID
MOATAZEDI DAVID's purchase track record
MOATAZEDI DAVID has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/26/2026 | BMRA | $16K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Biomerica reports Q1 earnings with lower EPS and sales. Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.
Transaction History
| EOLS | ▼ Sell | Open Market | 105,108 | $950K | 9/2/2026 | View on chart |
| BMRA | ▲ Buy | Open Market | 10,000 | $16K | 8/26/2026 | View on chart |
| EOLS | ▼ Sell | Open Market | 13,669 | $65K | 3/20/2026 | View on chart |
| EOLS | ▼ Sell | Open Market | 116,720 | $571K | 3/17/2026 | View on chart |
| EOLS | ▲ Buy | Option Exercise | 67,489 | $0 | 3/16/2026 | View on chart |
| EOLS | ▲ Buy | Grant | 313,212 | $0 | 2/17/2026 | View on chart |
| EOLS | ▼ Sell | Open Market | 10,539 | $75K | 12/22/2025 | View on chart |
| BMRA | ▲ Buy | Grant | 20,000 | $0 | 12/12/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 16,582 | $164K | 6/16/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 111,323 | $1.1M | 6/13/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 15,787 | $156K | 5/12/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 6,251 | $78K | 3/27/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 103,376 | $1.4M | 3/18/2025 | View on chart |
| EOLS | ▲ Buy | Grant | 95,399 | $0 | 3/7/2025 | View on chart |
| EOLS | ▼ Sell | Open Market | 10,502 | $114K | 12/23/2024 | View on chart |
| BMRA | ▲ Buy | Grant | 85,000 | $26K | 12/13/2024 | View on chart |
| EOLS | ▲ Buy | Option Exercise | 175,940 | $1.3M | 6/6/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 175,940 | $2.2M | 6/6/2024 | View on chart |
| EOLS | ▲ Buy | Option Exercise | 155,278 | $848K | 6/5/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 155,278 | $2.0M | 6/5/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 140,214 | $1.8M | 6/4/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 16,051 | $204K | 5/10/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 6,236 | $86K | 3/27/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 96,566 | $1.3M | 3/19/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 7,706 | $101K | 2/22/2024 | View on chart |
| EOLS | ▲ Buy | Grant | 61,202 | $0 | 2/21/2024 | View on chart |
| EOLS | ▲ Buy | Grant | 134,976 | $0 | 2/7/2024 | View on chart |
| EOLS | ▼ Sell | Open Market | 31,300 | $305K | 12/8/2023 | View on chart |
| EOLS | ▼ Sell | Open Market | 51,348 | $518K | 12/6/2023 | View on chart |
| EOLS | ▼ Sell | Open Market | 14,778 | $152K | 8/16/2023 | View on chart |
| EOLS | ▲ Buy | Grant | 91,803 | $0 | 8/14/2023 | View on chart |
| EOLS | ▼ Sell | Open Market | 6,110 | $52K | 3/27/2023 | View on chart |
| EOLS | ▼ Sell | Open Market | 64,211 | $544K | 3/14/2023 | View on chart |
| EOLS | ▲ Buy | Grant | 187,927 | $0 | 1/25/2023 | View on chart |
| EOLS | ▼ Sell | Open Market | 55,321 | $754K | 5/16/2022 | View on chart |
| EOLS | ▼ Sell | Open Market | 6,104 | $71K | 3/28/2022 | View on chart |
| EOLS | ▼ Sell | Open Market | 37,972 | $369K | 3/8/2022 | View on chart |
| EOLS | ▲ Buy | Grant | 214,286 | $0 | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Evolus (EOLS) Passes Momentum Screens
Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.
Evolus (EOLS) Passes Momentum Screens. Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.